Surrozen, Inc./DE

Item 1. Legal Proceedings

From time to time, we may be subject to legal proceedings. Other than as set forth below, we are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

In October 2026, Boehringer Ingelheim filed a request for arbitration with the International Court of Arbitration of the International Chamber of Commerce, or the ICC, asserting that we had materially breached the CLA and seeking a 50% reduction of its royalty and milestone payment obligations and repayment of $5.0 million of the June 2026 development milestone payment received in September 2026. The claims asserted are contractual in nature and do not relate to the safety or efficacy of SZN-413. In November 2026, we submitted our response to the ICC, denying the allegations in full. The arbitration proceedings may divert management’s time and attention and be costly, and could result in a reduction of future milestone and royalty payments to us, or the termination of the CLA. If the CLA is terminated, while the rights to SZN-413 would revert to us and Boehringer Ingelheim would no longer have any rights to develop or commercialize SZN-413, we would not be entitled to future milestone or royalty payments.